Basel: Roche has announced it has received CE Mark for its Elecsys pTau181 test to measure phosphorylated Tau (pTau) 181 ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

Swiss pharma giant Roche Holding AG (RHHBY) reported sales of CHF 30.9 billion for the first half of 2025, up 4% year over ...

Roche (RHHBY) plans direct-to-patient drug sales in the U.S. to avoid the influence from pharmacy benefit managers in product ...

Basel: Roche has received approval from the European Commission for Itovebi (inavolisib), in combination with palbociclib ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Roche ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, ...

The European Commission has approved Swiss pharma giant Roche’s Itovebi (inavolisib), in combination with palbociclib ...

Roche’s oral PI3K inhibitor Itovebi (inavolisib) has been approved by the European Commission (EC) as part of a combination treatment for advanced breast cancer patients.

The Swiss pharmaceutical giant Roche secured two significant regulatory victories, potentially strengthening its market position across key therapeutic areas. The European Commission granted ...